Metyrapone    (DrugBank: Metyrapone)

2 diseases
IDDisease name (Link within this page)Number of trials
75Cushing disease8
193Prader-Willi syndrome1

75. Cushing disease    [ 191 clinical trials,   172 drugs,   (DrugBank: 48 drugs),   61 drug target genes,   121 drug target pathways]
Searched query = "Cushing disease", "Cushing"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
8 / 191 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-000162-22-PL
(EUCTR)
27/07/201621/04/2016Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment periodProspective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing’s syndrome during a 12-week treatment period followed by an extension period of 24 weeks. - PROMPT Treatment of Cushing’s syndrome
MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Laboratoire HRA PharmaNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
55Phase 4Hungary;Belgium;Spain;Poland;Romania;Turkey;Germany;Italy
2EUCTR2014-000162-22-HU
(EUCTR)
06/10/201508/07/2015Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment periodProspective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing’s syndrome during a 12-week treatment period followed by an extension period of 24 weeks. - PROMPT Treatment of Cushing’s syndrome
MedDRA version: 18.1;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: metyrapone
INN or Proposed INN: METYRAPONE
Laboratoire HRA PharmaNULLNot RecruitingFemale: yes
Male: yes
70Phase 4Hungary;Spain;Poland;Belgium;Germany;Italy
3EUCTR2014-000162-22-DE
(EUCTR)
04/05/201530/10/2014Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment periodProspective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing’s syndrome during a 12-week treatment period followed by an extension period of 24 weeks. - PROMPT Treatment of Cushing’s syndrome
MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: Metopirone 250 mg capsules
Product Name: metyrapone
INN or Proposed INN: METYRAPONE
Laboratoire HRA PharmaNULLNot RecruitingFemale: yes
Male: yes
70Phase 4Hungary;Poland;Romania;Germany;Italy;Spain;Belgium;Turkey
4NCT02297945
(ClinicalTrials.gov)
April 201519/11/2014Effects of Metyrapone in Patients With Endogenous Cushing's SyndromeProspective, Single Arm, Open-label, Multicenter, International Study to Assess the Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome During a 12-week Treatment Period Followed by an Extension Period of 24 WeeksCushing's SyndromeDrug: metyraponeHRA PharmaNULLCompleted18 YearsN/AAll50Phase 3Belgium;Germany;Hungary;Italy;Poland;Romania;Spain;Turkey
5EUCTR2014-000162-22-IT
(EUCTR)
19/03/201525/11/2014Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment periodProspective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing’s syndrome during a 12-week treatment period followed by an extension period of 24 weeks. - PROMPT Treatment of Cushing’s syndrome
MedDRA version: 17.1;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: Metopirone 250 mg capsules/Cormeto
Product Name: metyrapone
INN or Proposed INN: METYRAPONE
Laboratoire HRA PharmaNULLNot RecruitingFemale: yes
Male: yes
70Phase 4United States;Hungary;Spain;Poland;Belgium;Germany;Switzerland;Italy;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2014-000162-22-BE
(EUCTR)
11/03/201504/12/2014Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment periodProspective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing’s syndrome during a 12-week treatment period followed by an extension period of 24 weeks. - PROMPT Treatment of Cushing’s syndrome
MedDRA version: 17.1;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: Metopirone 250 mg capsules
Product Name: metyrapone
Laboratoire HRA PharmaNULLNot RecruitingFemale: yes
Male: yes
70Phase 4United States;Hungary;Spain;Poland;Belgium;Germany;Switzerland;Italy;Sweden
7EUCTR2014-000162-22-ES
(EUCTR)
23/02/201516/01/2015Study to assess the effects of metyrapone in patients with Cushing?s syndrome during a 12-week treatment periodProspective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing?s syndrome during a 12-week treatment period followed by an extension period of 24 weeks. - PROMPT Treatment of Cushing?s syndrome
MedDRA version: 17.1;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: Metopirone 250 mg capsules
Product Name: metyrapone
INN or Proposed INN: METYRAPONE
Laboratoire HRA PharmaNULLNot RecruitingFemale: yes
Male: yes
70Phase 3United States;Hungary;Poland;Belgium;Spain;Germany;Italy;Switzerland;Sweden
8EUCTR2013-002063-26-IT
(EUCTR)
08/09/201323/07/2013A trial with Metyrapone in Cushing's syndromeA prospective open-label Phase 2 study of METYRAPONE as a preoperative treatment in patients with ACTH-independent Cushing’s syndrome due to adrenal adenoma. - METYX01 Cushing's syndrome;Therapeutic area: Diseases [C] - Hormonal diseases [C19]Trade Name: Matyrapone
Product Name: Metyrapone
Product Code: Metyrapone
S.C.D.U. MEDICINA INTERNA 1 Ospedale San Luigi OrbassanoNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
15Phase 2Italy

193. Prader-Willi syndrome    [ 95 clinical trials,   104 drugs,   (DrugBank: 27 drugs),   50 drug target genes,   63 drug target pathways]
Searched query = "Prader-Willi syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 95 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02368379
(ClinicalTrials.gov)
March 20145/2/2015Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi SyndromeDiagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi SyndromePrader Willi Syndrome;Adrenal InsufficiencyOther: Low dose (1 mcg) ACTH stimulation test;Other: Overnight metyrapone testNationwide Children's HospitalNULLCompleted2 YearsN/AAll23N/AUnited States